The UK guidelines for the management of soft tissue sarcomas (STS) provide updated recommendations for the diagnosis, treatment, and follow-up of these rare tumours. These guidelines, developed by a panel of UK sarcoma specialists, aim to improve the quality of care by ensuring consistent and optimal treatment, recruitment to clinical trials, and the accumulation of further data. They build on previous versions published in 2010 and 2016 and include specific sections on the management of sarcomas at defined anatomical sites, such as gynaecological, retroperitoneal, breast, and skin sarcomas. These tumours are generally managed by site-specific multidisciplinary teams linked to regional sarcoma specialist teams. The guidelines emphasize the importance of early referral to specialist regional soft tissue sarcoma services for suspected STS. Once diagnosed, the main treatment is usually surgical excision, often combined with pre- or post-operative radiotherapy for high-risk tumours. Systemic anti-cancer therapy may be used for certain subtypes. Regular follow-up is recommended to monitor local control, metastatic disease, and treatment effects. The guidelines also address the importance of multidisciplinary teams (MDTs) in the management of STS, including radiologists, surgeons, oncologists, pathologists, and specialist nurses. MDTs hold weekly meetings to discuss new cases and patients with high diagnostic suspicion. The guidelines also cover the role of imaging, biopsy, histology, and staging in the diagnosis and management of STS. The guidelines highlight the importance of accurate diagnosis through percutaneous core needle biopsy and the need for specialist pathologists to review biopsies. They also discuss the use of imaging techniques such as MRI and CT for staging and the role of molecular diagnostics in confirming pathognomonic genetic markers. The guidelines provide recommendations for the management of localised disease, including surgery, radiotherapy, and chemotherapy. They emphasize the importance of a multidisciplinary approach, with decisions made by the MDT. The guidelines also address the use of isolated limb perfusion, radiotherapy, and chemotherapy in the treatment of STS, as well as the importance of follow-up and monitoring for recurrence. Overall, the guidelines aim to improve the quality of care for patients with STS by providing a framework for multidisciplinary management, ensuring consistent treatment, and supporting ongoing research and data collection.The UK guidelines for the management of soft tissue sarcomas (STS) provide updated recommendations for the diagnosis, treatment, and follow-up of these rare tumours. These guidelines, developed by a panel of UK sarcoma specialists, aim to improve the quality of care by ensuring consistent and optimal treatment, recruitment to clinical trials, and the accumulation of further data. They build on previous versions published in 2010 and 2016 and include specific sections on the management of sarcomas at defined anatomical sites, such as gynaecological, retroperitoneal, breast, and skin sarcomas. These tumours are generally managed by site-specific multidisciplinary teams linked to regional sarcoma specialist teams. The guidelines emphasize the importance of early referral to specialist regional soft tissue sarcoma services for suspected STS. Once diagnosed, the main treatment is usually surgical excision, often combined with pre- or post-operative radiotherapy for high-risk tumours. Systemic anti-cancer therapy may be used for certain subtypes. Regular follow-up is recommended to monitor local control, metastatic disease, and treatment effects. The guidelines also address the importance of multidisciplinary teams (MDTs) in the management of STS, including radiologists, surgeons, oncologists, pathologists, and specialist nurses. MDTs hold weekly meetings to discuss new cases and patients with high diagnostic suspicion. The guidelines also cover the role of imaging, biopsy, histology, and staging in the diagnosis and management of STS. The guidelines highlight the importance of accurate diagnosis through percutaneous core needle biopsy and the need for specialist pathologists to review biopsies. They also discuss the use of imaging techniques such as MRI and CT for staging and the role of molecular diagnostics in confirming pathognomonic genetic markers. The guidelines provide recommendations for the management of localised disease, including surgery, radiotherapy, and chemotherapy. They emphasize the importance of a multidisciplinary approach, with decisions made by the MDT. The guidelines also address the use of isolated limb perfusion, radiotherapy, and chemotherapy in the treatment of STS, as well as the importance of follow-up and monitoring for recurrence. Overall, the guidelines aim to improve the quality of care for patients with STS by providing a framework for multidisciplinary management, ensuring consistent treatment, and supporting ongoing research and data collection.